Herborium Group starts the commercialization of its sexual health formulas; ready to take advantage of $1.5 billion market.

Fort Lee, New Jersey, Sept. 11, 2014 (GLOBE NEWSWIRE) -- Herborium Group, Inc., (HBRM) www.herborium.com, a Botanical Therapeutics® Company has announced today that it has signed an agreement with a Florida company to commercialize its proprietary, all botanical based sexual Botanical Therapeutics®: The Lasting Pleasure® for Women and Lasting Power® for Men. The products are going to be on the market in 4th quarter of 2014.

Lasting Pleasure® and Lasting Power® represent over $1.5 billion market potential for natural sexual health products and has already been featured in the USA Today, Sexual Health Issue: "Healthy Relationships". Natural sexual enhancement market is expected to grow to over $2 billion by 2018 as consumers opt for healthy life style improvement options.

In addition, there is a growing need for women sexual health products. Lasting Pleasure® for women responds to dramatic changes in women, and a society at large, attitudes to sexuality. The female sexual enhancement industry is poised for an explosion and is expected to grow into a multibillion dollar business as women themselves become increasingly aware of their sexuality and their sexual health. In 2012 the sales of female personal lubricants grew 41% and this growth has been followed by another 30% increase in 2013. There is no Viagra comparative product on the market for women and Herborium's Lasting Pleasure® for Women is the ONLY product of its kind.

Over 120% increase in revenues from sales of AcnEase® in 2013/14, and growing recognition of Herborium' brand, provide a solid foundation for launching Lasting Pleasure® and Lasting Power® as unique, all botanical Sexual Enhancement Therapeutics®.

About Herborium Group, Inc.

Herborium Group, Inc., a Botanical Therapeutics® company, focuses on developing, licensing, and marketing proprietary,botanical based medicinal products to consumers and healthcare professionals. The Company uses clinical validation to establish and maintain a differential advantage. The company sells its products in the US and Europe. For more information, please visit www.herborium.com, www.herboriumsh.com, and www.acnease.com.

One of our most important responsibilities is to communicate with shareholders in an open and direct manner. Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends." We cannot promise future returns. Our statements reflect our best judgment at the time, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events. The Company urges investors to review the risks and uncertainties contained within its filings with the OTC Markets and/or Securities and Exchange Commission.

CONTACT: For more information please inquire: Investorsrelations@herborium.com or tel. +2018494431

Source:Herborium Group, Inc.